← Oncology Approval Tracker

FDA DECISION ·

Tecentriq + Cotellic + Zelboraf

atezolizumab + cobimetinib + vemurafenib · Genentech

FDA approvalNew or expanded indicationMelanoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Unresectable or metastatic melanoma with a BRAF V600 mutation, in combination with cobimetinib and vemurafenib.

LAMPGEN ANALYSIS

Why it matters

Combined checkpoint inhibition with BRAF and MEK inhibition in a defined melanoma population.

What research teams should watch

Set up the targeted-treatment lead-in, then coordinate three agents and their toxicity monitoring.

Related study operations checklist

See the staffing responsibilities, timing, and handoff questions for this study setting.

BRAF-selected unresectable or metastatic melanoma

PRIMARY RECORDS

Sources